Scalp-Ear-Nipple Syndrome (SENS) Cell Models for Research

Scalp-Ear-Nipple Syndrome (SENS) is an extremely rare genetic disorder, with fewer than 100 cases reported worldwide. It is inherited in an autosomal dominant pattern, often arising from de novo mutations. The condition is characterized by aplasia cutis congenita of the scalp, malformed ears, and hypoplastic nipples. While not life-threatening, the syndrome can have significant cosmetic and functional impacts. Due to its rarity, precise epidemiological data are limited; however, the National Organization for Rare Disorders (NORD) and Online Mendelian Inheritance in Man (OMIM) provide clinical summaries. The syndrome is not associated with increased mortality or cancer risk, but its study offers insights into developmental pathways.

SENS serves as an excellent model for studying ectodermal development and the role of specific genes in skin, ear, and breast tissue formation. The two known causative genes, TP63 and KCTD1, are involved in crucial signaling pathways. Research on SENS can elucidate mechanisms of transcriptional regulation and protein-protein interactions. Public datasets, such as those in ClinVar and the Human Gene Mutation Database (HGMD), provide variant information. Open questions include the full spectrum of phenotypic variability and the molecular basis of incomplete penetrance.

SENS is not a cancer predisposition syndrome, but the affected genes play roles in pathways relevant to cancer and development. The major pathways include:

• • TP63 signaling: TP63 encodes p63, a transcription factor critical for epithelial development. It regulates genes involved in cell adhesion, proliferation, and differentiation. Mutations in TP63 can disrupt its function, leading to developmental defects.
• • KCTD1-mediated regulation: KCTD1 is a potassium channel tetramerization domain-containing protein that interacts with the Wnt signaling pathway. It modulates the transcriptional activity of β-catenin, affecting cell fate decisions.
• • Wnt/β-catenin pathway: KCTD1 negatively regulates Wnt signaling by promoting β-catenin degradation. Mutations in KCTD1 may lead to aberrant Wnt activation, impacting development.

Data from ClinVar and literature (Rinne et al., 2006; Nat Genet; Online sources).

The deregulated networks in SENS include:

• • Wnt/β-catenin pathway: KCTD1 mutations disrupt its ability to promote β-catenin degradation, leading to increased Wnt signaling. This affects cell proliferation and differentiation.
• • p63 transcriptional network: TP63 mutations alter the expression of downstream targets such as Jagged1, Notch, and components of the hedgehog pathway, impacting epithelial morphogenesis.
• • Cell adhesion and migration: p63 regulates genes like E-cadherin and integrins, influencing cell-cell interactions and tissue architecture.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate ectodermal development and are useful for studying SENS mutations in a 3D context.

• • Genetically engineered mouse models (GEMMs): Mice with conditional knockout of Tp63 or Kctd1 have been generated to study developmental roles. For example, Tp63 knockout mice exhibit severe skin and limb defects.
• • Patient-derived xenografts (PDX): Not applicable for SENS as it is not a cancer.
• • Induced models: CRISPR-engineered cell lines with specific TP63 or KCTD1 mutations can be used for in vitro studies.

CRISPR-based gene editing allows the creation of isogenic cell lines with specific SENS-associated mutations. For example:

• • TP63 knockout cell lines: Generated by introducing frameshift mutations in TP63, these lines can be used to study loss-of-function effects on epithelial differentiation.
• • KCTD1 point-mutation knock-in lines: Introducing a specific missense mutation (e.g., p.R62W) into a wild-type background allows the study of dominant-negative effects.

These sequence-verified models are commercially available from various sources, ensuring reproducibility and accelerating research. They are essential for functional validation and drug screening.

Gene-edited cell lines enable functional validation of SENS-associated variants. For example, a TP63 knockout line can be used to identify downstream target genes via transcriptomic analysis. Similarly, KCTD1 mutant lines can be used to assess the impact on Wnt signaling activity using reporter assays.

Isogenic pairs (wild-type vs. mutant) are powerful tools for drug screening. For SENS, compounds that modulate Wnt signaling could be tested for their ability to rescue the mutant phenotype. Additionally, these models can be used to screen for drugs that restore p63 function in TP63-mutant cells.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal only in the context of SENS mutations. This approach could reveal novel therapeutic targets for conditions with dysregulated p63 or Wnt signaling.